Key Milestone in Lucid-MS Development
Quantum BioPharma Ltd. (NASDAQ: QNTM) has reached a significant milestone in its drug development journey for Multiple Sclerosis with the completion of dosing in critical 90-day repeated dose oral toxicity and toxicokinetic studies for its promising candidate, Lucid-21-302, also known as Lucid-MS. This advancement is crucial for supporting an Investigational New Drug (IND) application with the US FDA, which allows for further clinical trials.
Advancing Clinical Development
Dr. Andrzej Chruscinski, the Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, expressed his enthusiasm about this achievement, stating, "These results will play a pivotal role in our IND submission planned for later this year." The completion of these studies propels the company closer to moving into Phase 2 trials, which are critical for evaluating the efficacy of Lucid-21-302 in patients diagnosed with Multiple Sclerosis.
Company Leaders Share Excitement
CEO Zeeshan Saeed shared his excitement regarding Lucid-21-302, emphasizing its potential as a first-in-class treatment. "Completing these studies brings us one step closer to making a meaningful difference in the lives of those living with Multiple Sclerosis," he stated. Saeed’s optimism reflects the company’s broader mission to deliver innovative treatments for challenging conditions, including neurodegenerative and metabolic disorders.
About Quantum BioPharma
Quantum BioPharma, listed on NASDAQ as QNTM, is actively working on a portfolio of advanced biotech solutions that target severe health issues. Its ongoing research into Lucid-MS—a patented new chemical entity—aims to prevent and reverse myelin degradation, a significant factor in the progression of Multiple Sclerosis. Exploration of therapies like Lucid-MS demonstrates the company’s commitment to addressing unmet medical needs.
Innovative Products and Future Prospects
Besides its focus on Lucid-MS, Quantum BioPharma's evolution includes the development of a consumer product, unbuzzd™, which has been successfully integrated into a venture with Celly Nutrition Corp. The collaboration not only empowers Quantum BioPharma with a substantial ownership stake but also establishes a revenue generation model through royalty arrangements. This diverse strategic direction underscores Quantum's innovative spirit and entrepreneurial approach in the biopharmaceutical landscape.
Investor Relations and Contact Information
To foster ongoing communication with investors and stakeholders, Quantum BioPharma maintains dedicated contact lines. For investor inquiries, individuals can reach out via email at IR@QuantumBioPharma.com. General inquiries can be directed to info@QuantumBioPharma.com. The company is dedicated to transparency and aims to keep stakeholders informed about its progress and future developments.
Frequently Asked Questions
What is Lucid-21-302?
Lucid-21-302, or Lucid-MS, is a novel therapeutic candidate developed by Quantum BioPharma aimed at treating Multiple Sclerosis by preventing myelin degradation.
What are toxicity studies and why are they important?
Toxicity studies assess the safety profile of a drug. They are crucial for obtaining regulatory approvals necessary for progressing to human trials.
What are the future plans for Lucid-21-302?
The next steps include analyzing the toxicity study data and preparing for Phase 2 clinical trials to assess the efficacy of Lucid-21-302 in patients with Multiple Sclerosis.
How does Quantum BioPharma generate revenue?
The company generates revenue by partnering with Celly Nutrition, which markets unbuzzd™, and through royalty payments linked to product sales.
How can I contact Quantum BioPharma?
For inquiries, individuals can reach Quantum BioPharma via their investor relations email or general inquiries email provided on their website.
